Comment from Anonymous

Summary: Anna, a patient and advocate for rare ovarian and endometrial cancers, supports the FDA's drug repurposing initiative. She specifically urges the FDA to consider Anktiva as a high-priority candidate for repurposing to treat rare cancers with limited treatment options.